Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | The role of immunotherapy in multiple myeloma

James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, discusses immunotherapy approaches in multiple myeloma treatment. Monoclonal antibodies such as daratumumab and isatuximab, which target CD38, as well as elotuzumab, which targets SLAMF7, have proven to be effective against multiple myeloma as part of combination therapy. Antibody-drug conjugates including the anti-B cell maturation antigen (BCMA) belantamab mafodotin have also shown to demonstrate anti-tumor activity. Dr Berenson additionally describes novel immunotherapy approaches including bi-specific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR)-T cells. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker